Imperial College London
Portrait Picture

ProfessorJenniferQuint

Faculty of Medicine, School of Public Health

Professor of Respiratory Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 8821j.quint

 
 
//

Location

 

.922Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Tran:2020:10.1183/13993003.02363-2019,
author = {Tran, T and King, E and Sarkar, R and Nan, C and Rubino, A and O'Leary, C and Muzwidzwa, R and Belton, L and Quint, J},
doi = {10.1183/13993003.02363-2019},
journal = {European Respiratory Journal},
title = {Oral corticosteroid prescription patterns for asthma in France, Germany, Italy, and the United Kingdom},
url = {http://dx.doi.org/10.1183/13993003.02363-2019},
volume = {55},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Oral corticosteroids (OCS) are used to manage asthma exacerbations and severe, uncontrolled asthma, but OCS use is associated with adverse effects. We aimed to describe the patterns of OCS use in the real-world management of patients with asthma in western Europe.We used electronic medical records from databases in France, Germany, Italy, and the United Kingdom from July 2011 through February 2018. Patients aged ≥12years with an asthma diagnosis, ≥1 non-OCS asthma medication within ±6months of diagnosis, and available data ≥6months prior to and ≥90days after cohort entry were included. High OCS use was defined as OCS ≥450mg prescribed in a 90-day window during follow-up. Baseline characteristics and OCS use during follow-up were described overall and by OCS use status.Of 702685 patients with asthma, 14–44% were OCS users and 6–9% were high OCS users at some point during follow-up. Annual prevalence of high OCS use across all countries was approximately 3%. High OCS users had a mean 1–3 annual OCS prescriptions, with an average daily OCS dosage of 1.3–2.2mg. For patients who continued to meet the high use definition, daily OCS exposure was generally stable at 5.5–7.5mg for at least 2years, increasing the risk of adverse effects.Our study demonstrates that OCS use is relatively common across the four studied European countries. Data from this study may provide decisive clinical insights to inform primary care physicians and specialists involved in the management of severe, uncontrolled asthma.
AU  - Tran,T
AU  - King,E
AU  - Sarkar,R
AU  - Nan,C
AU  - Rubino,A
AU  - O'Leary,C
AU  - Muzwidzwa,R
AU  - Belton,L
AU  - Quint,J
DO  - 10.1183/13993003.02363-2019
PY  - 2020///
SN  - 0903-1936
TI  - Oral corticosteroid prescription patterns for asthma in France, Germany, Italy, and the United Kingdom
T2  - European Respiratory Journal
UR  - http://dx.doi.org/10.1183/13993003.02363-2019
UR  - http://hdl.handle.net/10044/1/78190
VL  - 55
ER  -
Download